Nymox Pharmaceutical's NicAlert&#0153 Has Achieved Widespread Acceptance in Tobacco-Related Research Studies

Published: Mar 27, 2013

HASBROUCK HEIGHTS, N.J., March 27, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today that the Company's FDA Cleared NicAlertâ„¢ product continues to achieve widespread acceptance around the world as an important tool in tobacco-related research studies and programs in a broad range of healthcare areas. Researchers in the UK, Canada, Holland, Switzerland, Australia, Brazil, India, and Hong Kong as well as those in major research institutions across the U.S. are employing NicAlertâ„¢ in their studies as reported in many new and recent peer-reviewed publications.

Back to news